<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39444704</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Emerging trends and challenges in multiple sclerosis in Europe: rethinking classification and addressing COVID-19 impact.</ArticleTitle><Pagination><StartPage>101017</StartPage><MedlinePgn>101017</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101017</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2024.101017</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korsukewitz</LastName><ForeName>Catharina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiendl</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><CoiStatement>CK received grants/research support/honoraria for lectures or travel support from Biogen, Bristol Myers Squibb, Kohlhammer, Merck, Roche, Sanofi Genzyme. HW received grants/contracts/consulting fees/honoraria for lectures, presentations, manuscripts, speakers bureau, advisory boards, support for attending meetings from Deutsche Forschungsgemeinschaft (DFG), Deutsche Myasthenie Gesellschaft e.V., European Union, Alexion, Amicus Therapeutics Inc., Argenx, Biogen CSL, Behring, F. Hoffmann–La Roche Genzyme, Merck KgaA, Novartis, Roche, UCB, Biopharma, Argobio, Bristol Myers Squibb, Dianthus, EMD Serono, Fondazione Cariplo Idorsia, Immunic, Immunovant, INmune Bio_Syneos Health, Janssen, LTS, Lundbeck, Merck, Muna Therapeutics, Myrobalan Therapeutics, Novartis, PSL Group, Red Nucleus, Roche, Samsung, Sangamo, Sanofi, Swiss Multiple Sclerosis Society, Teladochealth, Toleranzia UCB, Viatris, AOCN, CEMCAT AstraZeneca, BGP Products Operations GmbH, EPG Health/Medthority, Kohlhammer, MS at the Limits, Neurodiem, NMSS, Ology, Sanofi, Springer, Streamed up, TEVA, Uvet, WebMD Global, AstraZeneca, NMSS, Biocryst, Cellerys, Galapagos, uniQure biopharma B.V.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444704</ArticleId><ArticleId IdType="pmc">PMC11496966</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2024.101017</ArticleId><ArticleId IdType="pii">S2666-7762(24)00184-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jakimovski D., Bittner S., Zivadinov R., et al. Multiple sclerosis. Lancet. 2024;403(10422):183–202. doi: 10.1016/S0140-6736(23)01473-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01473-3</ArticleId><ArticleId IdType="pubmed">37949093</ArticleId></ArticleIdList></Reference><Reference><Citation>Magyari M., Joensen H., Kopp T.I., Pontieri L., Koch-Henriksen N. Changes in prognosis of the Danish multiple sclerosis population over time. Mult Scler. 2022;28(14):2190–2201. doi: 10.1177/13524585221110582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585221110582</ArticleId><ArticleId IdType="pubmed">35822309</ArticleId></ArticleIdList></Reference><Reference><Citation>Portaccio E., Magyari M., Havrdova E.K., et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977. doi: 10.1016/j.lanepe.2024.100977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2024.100977</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperini L., Arrambide G., Celius E.G., et al. COVID-19 and multiple sclerosis: challenges and lessons for patient care. Lancet Reg Health Eur. 2024;44:100979. doi: 10.1016/j.lanepe.2024.100979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2024.100979</ArticleId><ArticleId IdType="pmc">PMC11486927</ArticleId><ArticleId IdType="pubmed">39429966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganjgahi H., Häring D., Graham G., et al. An agnostic approach for multiple sclerosis disease states and prognosis using artificial intelligence: four clinical states allow description of the disease and its probabilities for evolution MSMilan2023 – oral Presentations. Mult Scler J. 2023;29(3_suppl):4–136.</Citation></Reference><Reference><Citation>Lublin F.D., Häring D.A., Ganjgahi H., et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147–3161. doi: 10.1093/brain/awac016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac016</ArticleId><ArticleId IdType="pmc">PMC9536294</ArticleId><ArticleId IdType="pubmed">35104840</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller J., Cagol A., Lorscheider J., et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 2023;80(11):1232–1245. doi: 10.1001/jamaneurol.2023.3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2023.3331</ArticleId><ArticleId IdType="pubmed">37782515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap S.M., Al Hinai M., Gaughan M., et al. Vaccine hesitancy among people with multiple sclerosis. Mult Scler Relat Disord. 2021;56 doi: 10.1016/j.msard.2021.103236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103236</ArticleId><ArticleId IdType="pmc">PMC8411656</ArticleId><ArticleId IdType="pubmed">34507240</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M.I., Palaiodimou L., Theodorou A., et al. Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2023;29(4-5):585–594. doi: 10.1177/13524585221150881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585221150881</ArticleId><ArticleId IdType="pmc">PMC9895285</ArticleId><ArticleId IdType="pubmed">36722184</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Romero S., Lebrun-Frénay C., Reyes S., et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023;29(8):904–925. doi: 10.1177/13524585231168043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585231168043</ArticleId><ArticleId IdType="pmc">PMC10338708</ArticleId><ArticleId IdType="pubmed">37293841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>